Compare ADT Inc (ADT) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADT Inc vs Biogen Inc — how do they compare? ADT Inc trades at $7.35 (market cap $5.44B), while Biogen Inc trades at $208.67 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 5.5× ADT Inc's market cap, and ADT Inc pays a 2.95% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ADT | BIIB | |
|---|---|---|
Market Cap | $5.44B | $30.13B |
Sector | Industrials | Health |
52-Week High | $8.85 | $216.63 |
52-Week Low | $6.30 | $128.93 |
Enterprise Value | $13.13B | $37.20B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $7.31, down 2.66% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. The company shows solid fundamentals with a P/E of 10.35, net income margin of 11.86%, and consistent revenue growth, supported by positive analyst sentiment and institutional buying.
Outlook remains positive due to strong cash flow, dividend payments, and AI integration, but risks include high debt levels and competitive pressures. Wall Street consensus leans bullish with 47% buy ratings, suggesting potential upside if execution continues.
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
